Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer
NCT03146377
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
Capecitabine
DRUG:
Oxaliplatin
DRUG:
Irinotecan
Sponsor
The University of Hong Kong